key: cord-0970038-r733ocsn authors: Ling, Yunzhi; Zhong, Jiaying; Luo, Jiaru title: Safety and effectiveness of SARS‐CoV‐2 vaccines: A systematic review and meta‐analysis date: 2021-07-26 journal: J Med Virol DOI: 10.1002/jmv.27203 sha: b4c1e0c4ab0fedcc1bd4de7accb47df8092afd82 doc_id: 970038 cord_uid: r733ocsn Objective: To systematically evaluate the effectiveness and safety of the SARS‐CoV‐2 vaccines currently undergoing clinical trials. Methods: PubMed, EMBASE, and Cochrane Library databases were searched to collect open human COVID‐19 vaccines randomized controlled trials, without limiting the search time and language. The research papers collected in the above‐mentioned databases were initially screened according to the title and abstract content and merged, and the repeated ones were removed. After reading the full text of the remaining research, the studies that did not meet the inclusion criteria were excluded, and finally, nine studies were obtained. After extracting the statistical data of adverse events in the study, load them into Review Manager for heterogeneity analysis. Results: The incidence of adverse reactions of inactivated virus vaccines, RNA vaccines, and adenovirus vector vaccines was higher than that of placebo. Common adverse reactions included pain, swelling, and fever at the injection site. Conclusion: From the perspective of effectiveness, RNA vaccine > adenovirus vector vaccine > inactivated virus vaccine. From the perspective of safety, the incidence of adverse reactions of the three vaccines is higher than that of a placebo, and the incidence of adverse reactions of the adenovirus vector vaccine is higher. There are several vaccine types available for COVID- 19 3 and Sinovac Biotech 4 have been granted conditional market approval in China. Pfizer has received conditional marketing authorization for its RNA vaccine in the European Union. 5 CanSino has received conditional marketing authorization for its adenovirus vector vaccine in China. 6 Most of the vaccines that have received conditional marketing authorization are inactivated virus vaccines, RNA vaccines, and viral vector vaccines. For this reason, this article will make a systematic review of the three types of vaccines mentioned above. As far as we know, although several basic research and clinical trial results on the COVID-19 vaccine have been published, there is still a lack of comprehensive meta-analysis on the safety and effectiveness of the COVID-19 vaccine. We will summarize and analyze the effectiveness and adverse reactions of the current COVID-19 vaccine in clinical trials to provide important guidance for subsequent clinical applications. This study was designed based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. 7 Systematic literature searches were performed on PubMed, EMBASE, and Cochrane Library databases, respectively. The deadline for searching is March 9, 2021, and no language restriction was applied. Medical subject headings and free words, such as "COVID-19 Vaccines," "SARS-CoV-2 vaccine," "COVID-19 Virus Vaccines," "2019-nCoV vaccine," were used for search in the above databases. The search was limited to randomized controlled clinical trials in humans. The following conditions were required to be included in the study: (1) the type of trial was randomized controlled blinded trial; (2) the subjects were healthy people who had not been infected with SARS-CoV-2; (3) normal saline or adjuvant were used as controls, and no other vaccines were used as controls; (4) the study provides statistical information on adverse events following vaccination, including any adverse events, local adverse events, and systemic adverse events; (5) the intervention was administering COVID-19 vaccine. The retrieval results were screened with the help of Endnote and duplicate literature was eliminated. According to the research title and abstract, studies and reviews unrelated to this study were eliminated, and studies that did not meet the inclusion criteria were eliminated after reading the full text. Bias evaluation was performed on the included studies based on the Cochrane risk bias assessment tool 8 to assess the degree of bias risk in the randomization process, allocation concealment, blind application of subjects and investigators, integrity of study data, selective outcome reporting, and other bias risks. The first author of all studies, publication year, group information, phase of clinical trials, name and type of vaccine (Table 1 ) as well as any adverse events after vaccination, local adverse events, systemic adverse events, common adverse events that occur after vaccination (pain, erythema, swelling, fever, headache, and fatigue), combined with the antibody geometric average concentration, combined with the geometric mean titer of the antibody, statistics on vaccine efficacy was extracted into a predesigned table. Based on the Review Manager 5.3 software, the odds ratio (OR) of the binary variable results was analyzed. When I 2 < 50%, the fixed effects model was used, and when I 2 > 50%, the random effects model was used. between studies. Statistically, no heterogeneity was found with p value > 0.1, and vice versa. The flowchart for the study selection is shown in Figure 1 . The incidence of any adverse events after injection was higher in the vaccine group than in the placebo group (OR: 2.97, 95% confidence interval [CI]: 1.49-5.92, I 2 = 100%) ( Figure 3A ). Among them, the incidence of local adverse events was higher in the vaccine group (OR: 6.07, 95% CI: 2.13-17.28, I 2 = 96%); the incidence of systemic adverse events was lower than that of local adverse events (OR: 1.80, 95% CI: 1.02-3.17, I 2 = 87%). Among the common adverse events after injection, the vaccine group had a higher incidence than the placebo group ( Figure 3B) Figure 4C ). After RNA vaccine is injected into host cells, the encoded mRNA is 22%), and local adverse events were higher than those in the placebo group (OR: 13.89, 95% CI: 6.64-29.05, I 2 = 71%) ( Figure 6A ). There was only one paper with detailed statistics on common adverse events ( Figure 6B ), so further analysis could not be made. The occurrence of vaccine adverse events is dose-dependent. On the whole, the high-dose adenovirus vector vaccine group (OR: 5.1, 95% CI: 3.68-7.06, I 2 = 0%) has a lower incidence of adverse events than the low-dose group (OR: 6.31, 95% CI: 3.35-11.89, I 2 = 76%) ( Figure 6C ). However, it is interesting that the adverse events in the low-dose group were significantly stronger than those in the high-dose group in Sadoff's study. And in Zhu's study, the adverse events of the lowdose group were slightly lower than that of the high-dose group. Phase World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines China grants conditional approval for first COVID vaccine NMPA conditionally approves COVID-19 vaccine developed by Sinopharm's Wuhan Institute Sinovac COVID-19 vaccine granted conditional market approval in China Pfizer and BioNTech Receive authorization in the European Union for COVID-19 vaccine CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine in China The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebocontrolled, phase 2 trial A systematic review of SARS-CoV-2 vaccine candidates Advances in mRNA vaccines for infectious diseases Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis The authors declare that there are no conflict of interests.